Intellipharmaceutics International Inc. (IPCIF)
| Market Cap | 5.62M |
| Revenue (ttm) | 3.48M |
| Net Income (ttm) | -8.08M |
| Shares Out | 21.58M |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $0.2945 |
| Previous Close | $0.2900 |
| Change ($) | 0.0045 |
| Change (%) | 1.55% |
| Day's Open | 0.3000 |
| Day's Range | 0.2945 - 0.3000 |
| Day's Volume | 7,060 |
| 52-Week Range | 0.0588 - 0.48 |
News
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
About IPCIF
Intellipharmaceutics International, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hype... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Isa Odidi | Country Canada |
| Stock Exchange OTCMKTS | Ticker Symbol IPCIF |
Financial Performance
In 2019, IPCIF's revenue was $3.48 million, an increase of 103.21% compared to the previous year's $1.71 million. Losses were -$8.08 million, -41.19% less than in 2018.